不同分期非小细胞肺癌与Treg细胞、细胞因子相关研究

目的 探讨不同临床分期非小细胞肺癌外周血中CD4+CDhi25 CDlow127 Treg细胞、白介素(IL)-2、IL-10及干扰素(IFN)-γ的表达水平,并评价其之间的相关性.方法 采用流式细胞术检测55例非小细胞肺癌外周血CD4+CDhi25 CDlow127 Treg细胞占CD4+T细胞的比例,采用酶联免疫吸附反应检测IL-2、IL-10及IFN-γ值.比较不同临床分期肺癌CD4+CDhi25 CDlow127 Treg细胞、IL-2、IL-10及IFN-γ的表达水平,并进行相关性分析.结果 随着肺癌临床分期的增加,外周血中CD4+CDhi25 CDlow127 Treg细胞占CD4+T细胞的比例明显上升(P<0.05),IL-10值也明显升高(P<0.05);而IL-2、IFN-γ值则随肺癌临床分期的增加而明显下降(P<0.05).CD4+CDhi25 CDlow127Treg细胞与IL-10呈正相关性(P<0.05),IL-2与IFN-γ呈正相关性(P<0.05).CD4+CDhi25CDlow127Treg细胞、IL-10均与IL-2、IFN-γ 呈负相关性(P<0.05).结论 CD4+CDhi25 CDlow127 Treg细胞、IL-10的升高和IL-2、IFN-γ的下降可能是晚期肺癌患者抗肿瘤免疫低下、受抑制的原因之一,对其监测可作为评估晚期肺癌患者抗肿瘤免疫的参考指标.

On the correlation between different stages of non-small cell lung cancer with Treg cells and cytokines

Objective To investigate the expression of CD4+CDhi25CDlow127 regulatory T cells (Treg cell), IL-2, IL-10 and IFN-γin peripheral blood of patients with different TNM stages of non-small cell lung cancer( NSCLC) , and to evaluate their correlation. Methods The proportion of CD4+CDhi25 CDlow127 Treg cells to CD4+cell in peripheral blood of 55 NSCLC patients were determined by flow cytometry, and levels of IL-2, IL-10 and IFN-γ were measured by ELISA. The proportion of CD4+CDhi25 CDlow127 Treg cells, IL-2, IL-10 and IFN-γ of patients with different TNM stages of NSCLC were compared, and correlation analysis was carried on. Results The proportion of CD4+CDhi25 CDlow127 Treg cells increased obviously together with the increasing of TNM stages of NSCLC(P<0. 05),so did the level of IL-10 (P<0. 05). On the other hand, the level of IL-2 and IFN-γdecreased apparently with the increasing of TNM sta-ges of NSCLC(P<0. 05). CD4+CDhi25CDlow127Treg cells and IL-10 were positively correlated(P <0. 05). IL-2 and IFN-γ were positively correlated too(P<0. 05). CD4+CDhi25CDlow127Treg cells and IL-10 were all negatively correlated with IL-2 and IFN-γ(P<0. 05). Conclusion The increasing of CD4+ CDhi25CDlow127Treg cells and IL-10 and the de-creasing of IL-2 and IFN-γ are possibly one of the reasons of antitumor immunity suppression in terminal NSCLC patients. The surveillance for them can be reference indicators to evaluate antitumor immunity status of terminal lung cancer patients.